Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 4/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44801 | 0.84 | CYP2C19 (1.00) | CYP2C19HPGDALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1478837 | 0.82 | MEN1 (0.66) | CYP2C19HPGDALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1477938 | 0.81 | ALDH1A1 (0.54) | CYP2C19HPGDALDH1A1SMN1; SMN2LMNA | |
| Carbamic Acid SCHEMBL28267319 | 0.81 | CYP2C19 (0.61) | CYP2C19HPGDALDH1A1SMN1; SMN2LMNA | |
| Urea SCHEMBL27623582 | 0.81 | CYP2C19 (0.61) | CYP2C19HPGDALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4046464 | 0.81 | CYP2C19 (0.62) | CYP2C19HPGDALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL724648 | 0.81 | CYP2C19 (0.72) | CYP2C19HPGDALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL11260584 | 0.81 | CYP2C19 (0.72) | CYP2C19HPGDALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL5935700 | 0.81 | CYP2C19 (0.72) | CYP2C19HPGDALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4050426 | 0.81 | CYP2C19 (0.72) | CYP2C19HPGDALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144368-A2 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
| US-20230348373-A1 | DEUTERATED DERIVATIVES OF 6,8-BIS(BENZYLSULFANYL)OCTANOIC ACID | RAFAEL PHARMACEUTICALS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| WO-2010144712-A1 | DERIVATIVES, REAGENTS, AND IMMUNOASSAY FOR DETECTING LEVETIRACETAM | SERADYN, INC. (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20090192202-A1 | ANDROGEN MODULATORS | PFIZER INC | 2009-07-30 | — | — | US | disclosed |
| US-7507860-B2 | Androgen modulators | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| CN-101252954-A | Hydrazide conjugates as imaging agents | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2008-08-27 | — | — | CN | disclosed |
| US-20070197641-A1 | Androgen modulators | HU LAIN-YEN | 2007-08-23 | — | — | US | disclosed |
| EP-1737813-A1 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100305-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| EP-0706512-A1 | ACETAMIDE DERIVATIVES AND THEIR USE FOR MODIFYING FEEDING BEHAVIOUR MODIFIERS | LABORATOIRE L. LAFON (FR) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001333-A1 | ACETAMIDE DERIVATIVES AND THEIR USE FOR MODIFYING FEEDING BEHAVIOUR MODIFIERS | LABORATOIRE L. LAFON (FR) | 1995-01-12 | — | — | WO | disclosed |
| US-4394520-A | SKIN DISORDERS | SOCIETE ANONYME DITE: L'OREAL (FR) | 1983-07-19 | — | — | US | disclosed |
| US-4204064-A | FOR TREATMENT OF SKIN OR SCALP | L'OREAL (FR) | 1980-05-20 | — | — | US | disclosed |
| US-4139635-A | Cysteamine derivatives for oral treatment of seborrhea | L'OREAL (FR) | 1979-02-13 | — | — | US | disclosed |
| US-4085217-A | DERIVATIVES OF CYSTEINE OR CYSTEAMINE | L'OREAL (FR) | 1978-04-18 | — | — | US | disclosed |
| US-4035492-A | Oral treatment of seborrhea with cysteamine derivatives | L'OREAL (FR) | 1977-07-12 | — | — | US | disclosed |
| US-3976781-A | SULFUR CONTAINING AMINES | L'OREAL (FR) | 1976-08-24 | — | — | US | disclosed |
| US-3950542-A | Cysteamine derivatives for oral treatment of seborrhea | L'OREAL (FR) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197641-A1 | Androgen modulators | AR, NR5A1, SHBG | CYP2C19 1149/4885HPGD 768/4885ALDH1A1 1373/4885 |
| US-20090192202-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | CYP2C19 1149/4885HPGD 768/4885ALDH1A1 1373/4885 |
| US-20230348373-A1 | DEUTERATED DERIVATIVES OF 6,8-BIS(BENZYLSULFANYL)OCTANOIC ACID | SCD5, DHCR7, BCL6 | CYP2C19 1131/4885HPGD 629/4885ALDH1A1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.